Lymphatic Transport of Halofantrine in the Conscious Rat When Administered as Either the Free Base or the Hydrochloride Salt: Effect of Lipid Class and Lipid Vehicle Dispersion

doi:10.1021/js9502229

Journal of Pharmaceutical Sciences

Volume 85, Issue 4, April 1996, Pages 357-361

https://doi.org/10.1021/js9502229 Get rights and content

Abstract

The intestinal lymphatic transport of halofantrine, an important, highly lipophilic antimalarial drug, has been studied in a conscious rat model after oral administration. In these studies, the lymphatic transport of Hf free base when coadministered with lipid was ∼20% of the administered dose compared with 5% transport after administration of the HCl salt with or without lipid. These differences in transport can be attributed to the increased lipophilicity of the free base (relative to the HCl salt) thereby facilitating greater association of Hf base with the products of luminal lipid digestion and the subsequent interaction with the intestinally derived chylomicrons responsible for lymphatic drug transport. In contrast to previous results in an anesthetized rat model where lymphatic transport was dependent on the characteristics of the intraduodenally administered lipid formulations, the lymphatic transport of Hf base in the conscious rat was independent of both the class of administered lipid (triglyceride or fatty acid) and the extent of formulation dispersion (micellar lipid or lipid solution). Considering the different lymphatic transport profiles of Hf base in the anesthetized and conscious rat models, it is proposed that the lipid vehicle effects observed in the intraduodenally dosed anesthetized model most likely reflects the lack of gastric processing by preduodenal lipase and the shear action of the stomach otherwise present in the conscious rat model.

References and Notes (16)

C.J.H. Porter et al.
J. Pharm. Sci.
(1996)
W.N. Charman et al.
Int. J. Pharm.
(1986)
A.J. Humberstone et al.
J. Pharm. Biomed. Anal.
(1995)
T. Noguchi et al.
Int. J. Pharm.
(1985)
W.N. Charman et al.
Int. J. Pharm.
(1986)
W.N. Charman et al.
Int. J. Pharm.
(1986)
K.A. Milton et al.
Br. J. Clin. Pharmacol.
(1989)
M. Cheema et al.
J. Pharm. Pharmacol.
(1986)

There are more references available in the full text version of this article.

Cited by (66)

Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat
2021, International Journal of Pharmaceutics
Orlistat is a pancreatic lipase (PL) inhibitor that inhibits dietary lipid absorption and is used to treat obesity. The oral bioavailability of orlistat is considered zero after administration in standard formulations. This is advantageous in the treatment of obesity. However, if orlistat absorption could be improved it has the potential to treat diseases such as acute and critical illnesses where PL transport to the systemic circulation via gut lymph promotes organ failure. Orlistat is highly lipophilic and may associate with intestinal lipid absorption pathways into lymph. Here we investigate the potential to improve orlistat lymph and systemic uptake through intestinal administration in lipid formulations (LFs). The effect of lipid type, lipid dose, orlistat dose, and infusion time on lymph and systemic availability of orlistat was investigated. After administration in all LFs, orlistat concentrations in lymph were greater than in plasma, suggesting direct transport via lymph. Lymph and plasma orlistat derivative concentrations were ~8-fold greater after administration in a long-chain fatty acid (LC-FA) compared to a lipid-free, LC triglyceride (LC-TG) or medium-chain FA (MC-FA) formulation. Overall, administration of orlistat in a LC-FA formulation promotes lymph and systemic uptake which may enable treatment of diseases associated with elevated systemic PL activity.
The biological fate of orally administered mPEG-PDLLA polymeric micelles
2020, Journal of Controlled Release
The biological fate of polymeric micelles (PMs) following oral administration was investigated in this study to better understand the contribution of transport of integral PMs to oral absorption. To track integral PMs, near-infrared fluorophores with aggregation-caused quenching properties were utilized to label PMs comprised of methoxy poly(ethylene glycol)-poly(D,L-lactic acid) (mPEG-PDLLA) copolymers and methoxy poly(ethylene glycol)-distearoyl phosphoethanolamine (DSPE-PEG). The particle size of PMs prepared from mPEG_2.5k-PDLLA_1.25k, mPEG_2.5k-PDLLA_2.5k, mPEG_5k-PDLLA_3k, mPEG_5k-PDLLA_5k and DSPE-PEG_2k was 24.5, 29.5, 34.0, 41.4 and 15.6 nm, respectively. After oral administration by gavage to rats, PMs were retained in the gastrointestinal tract for at least 4 h, and the copolymer block chain lengths did not have significant influence. The emergence of fluorescence in the blood and liver served as direct evidence to support oral absorption of integral PMs. Approximately 1–2% of intact particles were absorbed via the lymphatic pathway, but the total amount of PMs that reach the systemic circulation await further elucidation. Confocal laser scanning microscopy added more evidence to support the penetration of integral PMs into the basolateral tissues of microvilli. Cellular uptake efficiency was about 4–7% in Caco-2 cell lines for all PM groups, but was reduced to 1–3% in Caco-2/HT29-MTX co-culture models due to the hindrance by the mucus layers. Approximately 6–12% of integral PMs were transported across Caco-2/HT29-MTX/Raji monolayers, whereas only approximately one-tenth of that amount was transported across Caco-2 and Caco-2/HT29-MTX monolayers. Differences, but not statistically significant, were observed between PM groups in lymphatic uptake, biodistribution, cellular uptake and trans-monolayer transport, possibly owing to difference in block chain lengths as well as particle size. In conclusion, evidence obtained in this study supports penetration of integral PMs across the enteric epithelia, but the total amount may be limited.
Nano lipid based carriers for lymphatic voyage of anti-cancer drugs: An insight into the in-vitro, ex-vivo, in-situ and in-vivo study models
2020, Journal of Drug Delivery Science and Technology
Management of cancer by anti-cancer drugs through conventional approaches has presented tough challenges in clinical settings due to non-selective distribution and low bioavailability of cytotoxic drugs causing serious side-effects and multi drug resistance (MDR). Further, lymph node transmission is regarded as preliminary signs of cancer metastasis. Therefore, lipid based nano-carriers (liposomes, functionalized liposomes, solid lipid nanoparticles, polymer-lipid nanoparticles, nano-lipid carriers, self-micro/nanoemulsifying systems, lipid drug conjugate systems and lipid prodrugs) employing lymphatic voyage offer multitude of advantages like selective targeting to localized as well as metastatic conditions, enhanced bioavailability, controlled delivery and management of MDR conditions. For translational objectives lipid based nano-carriers have been tested on various experimental models, viz. in-vitro lipolysis, in-vitro cell permeation (Caco-2 cell line), in-vitro in-vivo correlations, ex-vivo (everted and non-everted gut sac), in-situ intestinal perfusion, in-vivo (small animals and large animals) and chylomicron flow blocking approach. Therefore, we have summarized for the very first time usefulness of all these models with their characteristics, advantages, shortcomings recent modifications and most importantly their applicability in preclinical and clinical settings for nano-lipid carrier based anti-cancer drug delivery with emphasis on lymphatic targeting. We have also reflected the usefulness of in-silico models as a non-invasive approach to predict lymphatic transport of lipid based nano-carriers. We suggest that successful and rapid clinical translation of lymph targeted nano-lipid carriers in cancer therapy can be attained using these models.
Considerations for Determining Direct Versus Indirect Functional Effects of Solubilizing Excipients on Drug Transporters for Enhancing Bioavailability
2020, Journal of Pharmaceutical Sciences
Citation Excerpt :
As a result, there has been a significant increase in the number of excipients available as solubility enhancers over the last 2 decades.79-81 Mechanisms for micellar uptake have been implicated in lymphatic delivery, so it is not clear if all the drug absorbed will appear in the systemic circulation.82-86 However, in the absence of well-defined transporter systems for micelles from the lumen or potential membrane interactions across the intestinal barrier, the absorption of free drug is considered the rate-determining factor for bioavailability.
Excipients used in drug formulations at clinically safe levels have been considered to be pharmacologically inert; however, numerous studies have suggested that many solubilizing agents may modulate drug transporter activities and intestinal absorption. Here, the reported interactions between various solubilizing excipients and drug transporters are evaluated to consider various potential underlying mechanisms. This forms the basis for debate in the field in regard to whether or not the effects are based on “direct” interactions or “indirect” consequences arising from the role of the excipients. For example, an increase in apparent drug solubility can give rise to saturation of transporters according to Michaelis-Menten kinetics. This is also drawing the attention of regulatory agencies as they seek to understand the role of formulation additives. The continued application of excipients as a tool in solubility enhancement is crucial in the drug development process, creating a need for additional data to verify the proposed mechanism behind these changes. A literature review is provided here with some guidance on other factors that should be considered to delineate the effects that arise from direct physiological interactions or indirect effects. The results of such studies may aid the rational design of bioavailability-enhancing formulations.
Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: Implications for lymphatic transport and absolute bioavailability studies
2012, Journal of Pharmaceutical Sciences
The clearance (Cl) and volume of distribution (V_ss) of a lipophilic, lymphatically transported drug, halofantrine (Hf) have been evaluated after intravenous delivery to the systemic circulation in ex vivo lymph and plasma, and compared with the data obtained after administration of a lipid-based emulsion and a lipid-free cosolvent formulation. Systemic Cl and V_ss were significantly lower (approximately twofold) after delivery of Hf in lymph or the emulsion when compared with the administration in plasma or the cosolvent formulation. Preadministration of drug-free lymph, immediately before administration of drug in plasma, however, resulted in plasma profiles consistent with that obtained after administration of drug in lymph/emulsion. Where drug and lipid entered the systemic circulation coincidentally, systemic Cl of Hf, therefore, appeared to be relatively unaffected by the route of entry to the systemic circulation (i.e. via the lymph or the blood), but more significantly altered by total plasma lipid levels. Because temporal changes to plasma lipid levels occur as a result of the absorption of formulation or food-derived lipids and the infusion of intravenous lipid emulsions, the current data suggest that a mismatch in plasma lipid levels after intravenous and oral administrations may lead to differences in drug Cl and errors in bioavailability assessment. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Association
Intestinal lymphatic transport for drug delivery
2011, Advanced Drug Delivery Reviews
Citation Excerpt :
Most of the studies have been performed in anesthetized rats, but conscious restrained and unrestrained models have been also described [121]. The unconscious (anesthetized) rat model has been used in various studies [130–135] with various degrees of modification in the site of cannulation, lymph fistulation, feeding and rehydration pre- and post-operative procedures, and dosing [121]. The model is well described elsewhere [131].
Intestinal lymphatic transport has been shown to be an absorptive pathway following oral administration of lipids and an increasing number of lipophilic drugs, which once absorbed, diffuse across the intestinal enterocyte and while in transit associate with secretable enterocyte lipoproteins. The chylomicron-associated drug is then secreted from the enterocyte into the lymphatic circulation, rather than the portal circulation, thus avoiding the metabolically-active liver, but still ultimately returning to the systemic circulation. Because of this parallel and potentially alternative absorptive pathway, first-pass metabolism can be reduced while increasing lymphatic drug exposure, which opens the potential for novel therapeutic modalities and allows the implementation of lipid-based drug delivery systems. This review discusses the physiological features of the lymphatics, enterocyte uptake and metabolism, links between drug transport and lipid digestion/re-acylation, experimental model (in vivo, in vitro, and in silico) of lymphatic transport, and the design of lipid- or prodrug-based drug delivery systems for enhancing lymphatic drug transport.

View all citing articles on Scopus

View full text

Research ArticlesLymphatic Transport of Halofantrine in the Conscious Rat When Administered as Either the Free Base or the Hydrochloride Salt: Effect of Lipid Class and Lipid Vehicle Dispersion

Abstract

J. Pharm. Sci.

Int. J. Pharm.

J. Pharm. Biomed. Anal.

Int. J. Pharm.

Int. J. Pharm.

Int. J. Pharm.

Br. J. Clin. Pharmacol.

J. Pharm. Pharmacol.

Research Articles
Lymphatic Transport of Halofantrine in the Conscious Rat When Administered as Either the Free Base or the Hydrochloride Salt: Effect of Lipid Class and Lipid Vehicle Dispersion